2023. C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s173. DOI:https://doi.org/10.25251/skin.7.supp.173.